CD274 and neoplasm: Results of in vivo MYCi-induced tumor regression capacity are shown to be promising since it enhances infiltration of immune cells into tumor microenvironment, upregulates PD-L1 on tumor cells, and synergies with anti-PD1 immunotherapy [681, 704].